Back to Search
Start Over
Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation.
- Source :
-
Clinical neuropharmacology [Clin Neuropharmacol] 1999 Nov-Dec; Vol. 22 (6), pp. 337-9. - Publication Year :
- 1999
-
Abstract
- We investigated the efficacy and safety of botulinum toxin A (BTX) manufactured from a new bulk strain for the treatment of cervical dystonia. This was a single-blinded retrospective comparison of length of benefit, subjective improvement, and complications of treatment in 50 patients treated with the old form of toxin designated 79-11 and the new toxin strain BCB2024. The mean duration of benefit of the 79-11 strain and the BCB2024 strain were the same. Subjective efficacy, measured on a -4 to +4 scale, demonstrated no difference between the two strains. Dysphagia occurred in 12% of patients injected with the 79-11 strain and 14% of subjects injected with the BCB2024 strain. We also used a clinician's global assessment that incorporated the duration of benefit, subjective efficacy, and complications as a secondary analysis. There was no significant difference between the two forms of botulinum toxin A according to this scale. We conclude that the 79-11 strain and the BCB2024 strain offer similar peak efficacy duration of benefit, and adverse events.
- Subjects :
- Adult
Aged
Anti-Dyskinesia Agents adverse effects
Botulinum Toxins adverse effects
Evaluation Studies as Topic
Female
Humans
Male
Middle Aged
Neurotoxins adverse effects
Retrospective Studies
Single-Blind Method
Anti-Dyskinesia Agents therapeutic use
Botulinum Toxins therapeutic use
Neurotoxins therapeutic use
Torticollis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0362-5664
- Volume :
- 22
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Clinical neuropharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 10626093